Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections
about
Administration of Extended Infusion Piperacillin-TazobactamWith the Use of Smart Pump Technology.Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Pulmonary penetration of piperacillin and tazobactam in critically ill patients.Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?New antibiotic dosing in infants.Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants.Pseudomonas aeruginosa treatment and transmission reduction.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Dosing antibiotics in neonates: review of the pharmacokinetic data.Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.Dose optimization of piperacillin/tazobactam in critically ill children.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project.Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance
P2860
Q33774704-761D1B46-046A-40CD-8555-C527E7948252Q33798203-4DCD6E9B-D20F-4AB6-A349-019459597681Q34216623-DC4DA118-CEDF-44F6-81A6-8C08370C8848Q36158212-D5B6CE06-A927-4A91-A7E5-245CF5858582Q36438111-9EC89B6E-2EBE-4297-A781-E98718465993Q36760879-387D904C-A2C7-4C93-8591-53AC3CB4684FQ37335725-93295976-121D-440B-AB60-6456EE6432D6Q37642084-7C125850-C5E8-455F-8E6B-7CF6821A683FQ37713019-44942244-7762-4FC0-8546-249050142BC3Q38131538-6FD67A83-FEF5-486D-AEAA-83FB3A234C02Q38138835-F217FF5A-9576-4212-8268-F1FBB505E692Q38649419-B1B0AA4E-EC51-4A18-9054-6B17CDA79443Q38819770-2AA1531B-D6DE-4D98-8197-A207EDEEE062Q38848103-E1DBB0A1-ED71-43D6-935B-A270936C75EAQ38896040-A9BFE8B9-8D85-454C-97D0-7767FB922D21Q39344408-E1530D4F-FE03-4B68-BF23-C4372D6DA6C4Q40087256-7673A682-E0A9-4BE4-92C6-2229585F120BQ40687385-D59DE686-3F0B-4B46-8678-AFC87C0D0077Q40714798-FC6690B7-F135-44B0-8F5B-7E28F89434C1Q40810754-707CC2F2-5A1C-498E-993E-902091CD1E00Q40922179-FD4E7799-3380-4768-8F85-E7E076A668CEQ41004466-B7AC4D4B-F83B-4536-BEBE-469DD926442FQ41139120-BD8FE5DC-559B-40EF-B852-11DC0F2EE2ADQ54261873-F9640358-C44E-4588-9F4B-C32D3CCE0BFBQ58700552-DF1CEFB0-C7C8-4503-9553-9E20310D7550
P2860
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Population pharmacokinetics of ...... nts with nosocomial infections
@ast
Population pharmacokinetics of ...... nts with nosocomial infections
@en
type
label
Population pharmacokinetics of ...... nts with nosocomial infections
@ast
Population pharmacokinetics of ...... nts with nosocomial infections
@en
prefLabel
Population pharmacokinetics of ...... nts with nosocomial infections
@ast
Population pharmacokinetics of ...... nts with nosocomial infections
@en
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... nts with nosocomial infections
@en
P2093
B M Lomaestro
G L Drusano
J M Butterfield
T P Lodise
P2860
P304
P356
10.1128/AAC.00521-12
P407
P577
2012-05-14T00:00:00Z